In a recent study published in the Journal of American Medical Association (JAMA) Oncology, researchers from California investigated the diagnostic outcomes of concurrent sequencing of ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics first implemented RNA testing in 2016 as part of a research and ...

Cancer is most treatable in its early stages, so finding innovative and non-invasive methods to diagnose cancer early on is crucial for fighting the disease. Liquid biopsies, which require just a ...

Performing RNA sequencing concurrently with DNA sequencing improves detection of novel variants and classification of existing variants, according to a study published online Nov. 4 in JAMA Oncology ...

VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...

The novel Cleavage High-throughput Assay (CHiTA) developed at Penn State provides a scarless method to characterize thousands of diverse small self-cleaving RNA enzymes, called twister ribozymes, in a ...

A new method to detect ribonucleic acid (RNA) without needing any complex lab procedures or heating equipment has been developed by researchers at UConn Health. Published in Nature Communications, ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary ...

A lab is developing more accurate and powerful liquid biopsy technologies that take advantage of signals from RNA 'dark matter,' an understudied area of the genome. Cancer is most treatable in its ...

image: UC Santa Cruz Assistant Professor of Biomolecular Engineering Daniel Kim and his lab are developing more accurate and powerful liquid biopsy technologies that take advantage of signals from RNA ...